Cargando…
Renin‐Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID‐19
BACKGROUND: Considering the widespread risk of collider bias and confounding by indication in previous research, the associations between renin‐angiotensin aldosterone system (RAAS) inhibitor use and COVID‐19 remain unknown. Accordingly, this study tested the hypothesis that RAAS inhibitors influenc...
Autores principales: | Loader, Jordan, Lampa, Erik, Gustafsson, Stefan, Cars, Thomas, Sundström, Johan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475700/ https://www.ncbi.nlm.nih.gov/pubmed/34320843 http://dx.doi.org/10.1161/JAHA.120.021154 |
Ejemplares similares
-
Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research
por: Loader, Jordan, et al.
Publicado: (2022) -
Prevention and management of hyperkalemia in patients treated with renin–angiotensin–aldosterone system inhibitors
por: Weinstein, Jordan, et al.
Publicado: (2021) -
Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19
por: Jarcho, John A., et al.
Publicado: (2020) -
Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
por: Vaduganathan, Muthiah, et al.
Publicado: (2020) -
Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
por: Benenson, Irina, et al.
Publicado: (2020)